Correlation between plasma VEGF and angiogenesis of skin and subcutaneous tissue cancer in dogs

• Autorzy: Sobczynska-Rak A.
• Języki publikacji: EN

Abstrakty

EN

The research was performed on tumour tissues removed from 42 dogs, as well as blood samples drawn from dogs suffering from skin and subcutaneous tissue tumours and healthy dogs comprising the control group. The tumour specimens were preserved in 10% buffered formalin for 24 h. The tumour types were classified according to the official WHO classification. Immunohistochemical staining was performed in order to render the vascular endothelium visible. In the quantitative analysis of the blood vessels, a system of computer assisted microscopic analysis was utilised. The blood was centrifuged and the obtained plasma was labelled for vascular endothelial growth factor (VEGF). The test results were read with the use of a TECAN microplate reader and Magellan 4.0 software, allowing for curvilinear characteristic. It was found that the level of the vascularisation of malignant tumours is higher than that of benign tumours, and correlates with a high level of VEGF in blood plasma.

• Wydawca: -
• Czasopismo: Bulletin of the Veterinary Institute in Puławy
• Rocznik: 2009
• Tom: 53
• Numer: 3
• Opis fizyczny: p.503-506,fig.,ref.

Twórcy

autor

Sobczynska-Rak A.

• Department of Veterinary Surgery, Faculty of Veterinary Medicine, Lublin University of Life Sciences, 20-612 Lublin, Poland

Bibliografia

• 1. Ascierto P.A., Leonardi E., Ottaiano A., Napolitano M., Scala S., Castello G.: Prognostic value of serum VEGF in melanoma patients: a pilot study. Anticancer Res 2004, 24, 4255-4258.
• 2. Barańska P., Jerczyńska H., Pawłowska Z.: Vascular endothelial growth factor-structure and functions. Postępy Biochem 2005, 51, 13-21.
• 3. Breier G., Risau W.: The role of vascular endothelial growth factor in blood vessel formation Cell Biol 1996, 6, 454-456.
• 4. Carmeliet P., Jain R.: Angiogenesis in cancer and other diseases. Nature 2000, 407, 249-257.
• 5. Chao C., Al-Saleem T., Brooks J.J., Rogatko A., Kraybill W.G., Eisenberg B.: Vascular endothelial growth factor and soft tissue sarcomas: tumor expression correlates with grade. Ann Surg Oncol 2001, 8, 260-267.
• 6. Czekierdowski A.: Studies on angiogenesis in the benign and malignant ovarian neoplasms with the use of color and pulsed Doppler sonography and serum CA-125, CA- 19.9, CA-72.4 and vascular endothelial growth factor measurements. Ann Univ Mariae Curie-Sklodowska (Med) 2002, 57, 113-131.
• 7. Ferrara N., Davis-Smyth T.: The biology of vascular endothelial growth factor. Endocr Rev 1997, 18, 4-25.
• 8. Ferrara N.: Molecular and biological properties of vascular endothelial growth factor. J Mol Med 1999, 77, 527-543.
• 9. Han H., Silverman J.F., Santucci T.S., Macherey R.S., dAmato T.A., Tung M.Y., Weyant R.J., Landreneau R.J.: Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis. Ann Surg Oncol 2001, 8, 72-79.
• 10. Kozaczka A., Najda J., Waszczyk D.: Angiogenesis controlling mechanisms and their clinical application in advanced cases of colorectal cancer. Współ Onkol 2004, 8, 373-378.
• 11. Kumar H., Heer K., Lee P.W., Duthie G.S., MacDonald A.W., Greenman J., Kerin M.J., Monson J.R.: Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer. Clin Cancer Res 1998, 4, 1279-1285.
• 12. Litwiniuk M., Łojko A., Thielemann A., Kopczyński Z.: Vascular endothelial growth factor (VEGF) and selected clinicopathological parameters in breast carcinoma. Współcz Onkologia 2007, 11, 300-304.
• 13. Loggini B., Boldrini L., Gisfredi S., Ursino S., Camacci T., De Jeso K., Cervadoro G., Pingitore R., Barachini P., Leocata P., Fontanini G.: C34 microvessel density and VEGF expression in basal and squamous cell carcinoma. Pathol Res Pract 2003,199, 705-712.
• 14. Łojko A., Komarnicki M.: Vascular endothelial growth factor in tumor angiogenesis. Współ Onkol 2004, 8, 1-4.
• 15. Nicosia R. F.: What is the role of vascular endothelial growth factor-related molecules in tumor angiogenesis? Am J Pathol 1998, 153, 11-16.
• 16. Rosen L.S.: Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers. Cancer Control 2002, 9, 36-44.
• 17. Scheidegger P., Weiglhofer W., Suarez S., Kaser-Hotz B., Steiner R., Ballmer-Hofer K., Jaussi R.: Vascular endothelial growth factor (VEGF) and its receptors in tumor-bearing dogs. Biol Chem 1999, 380, 1449-1454.
• 18. Stępień-Wyrobiec O., Wyrobiec G., Rokicki W., Harabin- Słowińska M.: Vascular endothelial growth factor (VEGF) - a regulator of angiogenesis. Ann Acad Med Silesien 2007, 61, 152-160.
• 19. Szala S., Radzikowski Cz.: Molecular basis of neoplastic angiogenesis. Nowotwory 1997, 47, 1-19.
• 20. Takahashi Y., Kitadi Y., Bucana C.D., Cleary K.R., Ellis L.M.: Expression of vascular endothelial growth facto rand its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995, 55, 3964-3968.
• 21. Wergin M.C., Kaser-Hotz B.: Plasma vascular endothelial growth factor (VEGF) measured in seventy dogs with spontaneously occurring tumors. In Vivo 2004, 18, 15-19.
• 22. Wergin M.C., Ballmer-Hofer K., Roos M., Achermann R.E., Inteeworn N., Akens M.K., Blattmann H., Kaser- Hotz B.: Preliminary study of plasma vascular endothelial growth factor (VEGF) during low- and high-dose radiation therapy of dogs with spontaneous tumors. Vet Radiol Ultrasound 2004, 45, 247-254.
• 23. Yuan B.A., Yu C.J., Kuo S.H., Chen W.J., Lin F.Y., Luh K.T., Yang P.C., Lee Y.C.: Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer. J Clin Oncol 2001, 19, 432-441.
• 24. Zheng S., Han M.Y., Xiao Z.X., Peng J.P., Dong Q.: Clinical significance of vascular endothelial growth factor expression and neovascularization in collateral carcinoma. Gastroenterology 2003, 9, 1227-1230.